866-997-4948(US-Canada Toll Free)

Amyotrophic lateral sclerosis (ALS)-Market Insights, Epidemiology and Market Forecast-2025

Published By :

DelveInsight

Published Date : Sep 2017

Category :

Pharmaceutical

No. of Pages : 70 Pages

DelveInsights Amyotrophic lateral sclerosis (ALS)-Market Insights, Epidemiology and Market Forecast-Market Insights, Epidemiology and Market Forecast-2025 report provides an overview of the disease and in depth research related to Amyotrophic lateral sclerosis (ALS)-Market Insights, Epidemiology and Market Forecast for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025.

This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Amyotrophic lateral sclerosis (ALS)-Market Insights, Epidemiology and Market Forecast. It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Amyotrophic lateral sclerosis (ALS)-Market Insights, Epidemiology and Market Forecast for 7 major markets. The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the Report highlights the frontrunners, the drivers and barriers for the Amyotrophic lateral sclerosis (ALS)-Market Insights, Epidemiology and Market Forecast market, as well as treatment algorithm, current treatments & advancements are included.
The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Amyotrophic lateral sclerosis (ALS)-Market Insights, Epidemiology and Market Forecast, providing an in-depth analysis of emerging therapies which will create an impact through their launch.
According to DelveInsight, the forecasted patient population of Amyotrophic lateral sclerosis (ALS)-Market Insights, Epidemiology and Market Forecast for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Amyotrophic lateral sclerosis (ALS)-Market Insights, Epidemiology and Market Forecast 7MM market size is estimated to be USD XX by 2025. The DelveInsight Report will help in enhanced understanding of the Amyotrophic lateral sclerosis (ALS)-Market Insights, Epidemiology and Market Forecast market from inside out, with transparency into the calculated patient forecasting data and estimated market size.
Key Coverage
Understanding historical and forecasted epidemiological data for Amyotrophic lateral sclerosis (ALS)-Market Insights, Epidemiology and Market Forecast covering 7MM from 2015-2025.
Segment level epidemiology and market split for Amyotrophic lateral sclerosis (ALS)-Market Insights, Epidemiology and Market Forecast.
The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Amyotrophic lateral sclerosis (ALS)-Market Insights, Epidemiology and Market Forecast.
The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2025 and detailed historical and forecasted Amyotrophic lateral sclerosis (ALS)-Market Insights, Epidemiology and Market Forecast market trends.
Thorough market distribution based on market share for Amyotrophic lateral sclerosis (ALS)-Market Insights, Epidemiology and Market Forecast.
Reasons to buy:
The report will help in developing business strategies by understanding trends shaping and driving the Amyotrophic lateral sclerosis (ALS)-Market Insights, Epidemiology and Market Forecast market.
To understand the future market competition in the Amyotrophic lateral sclerosis (ALS)-Market Insights, Epidemiology and Market Forecast market and Insightful review of the key market drivers and barriers.
Organize sales and marketing efforts by identifying the best opportunities for Amyotrophic lateral sclerosis (ALS)-Market Insights, Epidemiology and Market Forecast in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
1. Report Introduction
2. Amyotrophic lateral sclerosis (ALS) Market Overview at a Glance
2.1. Total Market Share Distribution of Amyotrophic lateral sclerosis (ALS) for 7 MM in 2016
2.2. Total Market Share Distribution of Amyotrophic lateral sclerosis (ALS) for 7 MM in 2025
3. Amyotrophic lateral sclerosis (ALS)
3.1.1. Overview
3.1.2. Symptoms
3.1.3. Pathophysiology
3.1.4. Staging
3.1.5. Diagnosis
3.1.6. Treatment
4. Epidemiology and Patient Population
4.1.1. United States
4.1.1.1. Diagnosed Cases of Amyotrophic lateral sclerosis (ALS) in United States
4.1.2. Germany
4.1.2.1. Diagnosed Cases of Amyotrophic lateral sclerosis (ALS) in Germany
4.1.3. France
4.1.3.1. Diagnosed Cases of Amyotrophic lateral sclerosis (ALS) in France
4.1.4. Italy
4.1.4.1. Diagnosed Cases of Amyotrophic lateral sclerosis (ALS) in Italy
4.1.5. Spain
4.1.5.1. Diagnosed Cases of Amyotrophic lateral sclerosis (ALS) in Spain
4.1.6. United Kingdom
4.1.6.1. Diagnosed Cases of Amyotrophic lateral sclerosis (ALS) in United Kingdom
5. Treatment Algorithm
5.1.1. Treatment Guidelines/Practices
6. Marketed Drugs for Amyotrophic lateral sclerosis (ALS)
6.1. Drug 1: Company A
6.1.1. Drug Description
6.1.2. Mechanism of Action
6.1.3. Regulatory Milestones
6.1.4. Advantages & Disadvantages
6.1.5. Safety and Efficacy
6.1.6. Product Profile
6.1.7. Patent Status
6.2. Drug 2: Company B
6.2.1. Drug Description
6.2.2. Mechanism of Action
6.2.3. Regulatory Milestones
6.2.4. Advantages & Disadvantages
6.2.5. Safety and Efficacy
6.2.6. Product Profile
6.2.7. Patent Status
7. Emerging Therapies
7.1. Drug 3: Company C
7.1.1. Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Product Profile
7.1.5. Launch Date
7.1.6. Clinical Development
7.1.7. Clinical Pipeline Activity
7.1.8. Ongoing Trials Information
7.1.9. Clinical Trial by Phase
7.2. Drug 4: Company B
7.2.1. Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Product Profile
7.2.5. Launch Date
7.2.6. Clinical Development
7.2.7. Clinical Pipeline Activity
7.2.8. Ongoing Trials Information
7.2.9. Clinical Trial by Phase
8. Overview of Total Amyotrophic lateral sclerosis (ALS) Market (2016 & 2025)
9. Amyotrophic lateral sclerosis (ALS): Country-Wise Market Analysis
9.1. United States
9.1.1. Historical Market Size (2015-2016)
9.1.2. Forecasted Market Size (2017-2025)
9.2. Germany Market Size
9.2.1. Historical Market Size (2015-2016)
9.2.2. Forecasted Market Size (2017-2025)
9.3. France Market Size
9.3.1. Historical Market Size (2015-2016)
9.3.2. Forecasted Market Size (2017-2025)
9.4. United Kingdom Market Size
9.4.1. Historical Market Size (2015-2016)
9.4.2. Forecasted Market Size (2017-2025)
9.5. Spain Market Size
9.5.1. Historical Market Size (2015-2016)
9.5.2. Forecasted Market Size (2017-2025)
9.6. Italy Market Size
9.6.1. Historical Market Size (2015-2016)
9.6.2. Forecasted Market Size (2017-2025)
9.7. Japan Market Size
9.7.1. Historical Market Size (2015-2016)
9.7.2. Forecasted Market Size (2017-2025)
10. Market Drivers
11. Market Restraints
12. Appendix
13. Report Methodology
14. Consulting Services
15. Disclaimer
16. About DelveInsight


List of Tables

Table 1: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in United States (2015-2025)
Table 2: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in Germany (2015-2025)
Table 3: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in France (2015-2025)
Table 4: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in Spain (2015-2025)
Table 6: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in Italy (2015-2025)
Table 7: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in Japan (2015-2025)
Table 8: List of Marketed Drugs for Amyotrophic lateral sclerosis (ALS)
Table 9: List of Pipeline Phase III Drugs for Amyotrophic lateral sclerosis (ALS)
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Table 17: Germany Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Table 18: France Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Table 20: Spain Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Table 21: Italy Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Table 22: Japan Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)

List of Figures
Figure 1: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in United States (2015-2025)
Figure 2: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in Germany (2015-2025)
Figure 3: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in France (2015-2025)
Figure 4: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in United Kingdom (2015-2025)
Figure 5: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in Spain (2015-2025)
Figure 6: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in Italy (2015-2025)
Figure 7: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in Japan (2015-2025)
Figure 8: List of Marketed Drugs for Amyotrophic lateral sclerosis (ALS)
Figure 9: List of Pipeline Phase III Drugs for Amyotrophic lateral sclerosis (ALS)
Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
Figure 11: Clinical Trials by Trial status, 2017
Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
Figure 13: Clinical Trials by Trial status, 2017
Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
Figure 15: Clinical Trials by Trial status, 2017
Figure 16: United States Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Figure 17: Germany Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Figure 18: France Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Figure 19: United Kingdom Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Figure 20: Spain Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Figure 21: Italy Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Figure 22: Japan Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Amyotrophic lateral sclerosis (ALS) Market (7MM)
Amyotrophic lateral sclerosis (ALS) Market forecasting
Amyotrophic lateral sclerosis (ALS) Sales forecasting
Amyotrophic lateral sclerosis (ALS) Market segments
Amyotrophic lateral sclerosis (ALS) Epidemiology
Amyotrophic lateral sclerosis (ALS) Pipeline products and technologies
Amyotrophic lateral sclerosis (ALS) Competitive landscape
Amyotrophic lateral sclerosis (ALS) SWOT analysis
Amyotrophic lateral sclerosis (ALS) Market Drivers and barriers
Amyotrophic lateral sclerosis (ALS) Key Companies and Funding

List of Table

Table 1: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in United States (2015-2025)
Table 2: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in Germany (2015-2025)
Table 3: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in France (2015-2025)
Table 4: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in Spain (2015-2025)
Table 6: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in Italy (2015-2025)
Table 7: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in Japan (2015-2025)
Table 8: List of Marketed Drugs for Amyotrophic lateral sclerosis (ALS)
Table 9: List of Pipeline Phase III Drugs for Amyotrophic lateral sclerosis (ALS)
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Table 17: Germany Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Table 18: France Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Table 20: Spain Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Table 21: Italy Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Table 22: Japan Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)

List of Chart

Figure 1: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in United States (2015-2025)
Figure 2: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in Germany (2015-2025)
Figure 3: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in France (2015-2025)
Figure 4: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in United Kingdom (2015-2025)
Figure 5: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in Spain (2015-2025)
Figure 6: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in Italy (2015-2025)
Figure 7: Diagnosed Cases Amyotrophic lateral sclerosis (ALS) in Japan (2015-2025)
Figure 8: List of Marketed Drugs for Amyotrophic lateral sclerosis (ALS)
Figure 9: List of Pipeline Phase III Drugs for Amyotrophic lateral sclerosis (ALS)
Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
Figure 11: Clinical Trials by Trial status, 2017
Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
Figure 13: Clinical Trials by Trial status, 2017
Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
Figure 15: Clinical Trials by Trial status, 2017
Figure 16: United States Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Figure 17: Germany Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Figure 18: France Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Figure 19: United Kingdom Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Figure 20: Spain Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Figure 21: Italy Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)
Figure 22: Japan Market Size of Amyotrophic lateral sclerosis (ALS) in USD, Million (2015-2025)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *